A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

Nom du journal : Breast Cancer Res

Année : 2019

Volume : 22

Page de départ : 1

Auteurs: Spicer J, Arimura A, Posner J, Garcia-Corbacho J, Baird RD, Campone M, Italiano A, Bonneterre J, Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Cresti N, Takeda Y,